Back to Browse Journals » Clinical Ophthalmology » Volume 2 » Issue 3

Pigmented basal cell carcinoma of the eyelid in Hispanics

Authors Lily Koo Lin, Han Lee, Eli Chang

Published Date October 2008 Volume 2008:2(3) Pages 641—643

DOI http://dx.doi.org/10.2147/OPTH.S2110

Published 6 October 2008

Lily Koo Lin1, Han Lee2, Eli Chang1

1Department of Oculoplastics, Doheny Eye Institute, Los Angeles, CA, USA; 2Department of Dermatology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA

Background: Pigmented basal cell carcinoma (PBCC) of the eyelid has not been well cited in the literature, and is often overlooked in the differential diagnosis of pigmented eyelid lesions. We aim to describe PBCC of the eyelid in Hispanic patients.

Methods: Retrospective review of patients with eyelid skin cancer who presented to the Department of Dermatology at the Keck School of Medicine of the University of Southern California and the Doheny Eye Institute from January 2002 to November 2005.

Results: Sixty-nine of the 79 patients with eyelid skin cancer had basal cell carcinoma. Eight of these patients were Hispanic. Four of the eight Hispanic patients had PBCC.

Conclusions: Although eyelid PBCC is regarded as a rare condition, it may occur more commonly in the Hispanic population and should be remembered in the differential diagnosis of pigmented eyelid lesions.

Keywords: pigmented basal cell carcinoma, eyelid, skin cancer, lesions

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia

Odd Erik Johansen, Pål Johan Vanberg, Bente Kvarv Kilhovd, Anders Palmstrøm Jørgensen

Vascular Health and Risk Management 2009, 5:121-128

Published Date: 18 December 2008

Health literacy and health seeking behavior among older men in a middle-income nation

Paul A Bourne, Chloe Morris, Christopher AD Charles, et al

Patient Related Outcome Measures 2010, 1:39-49

Published Date: 26 May 2010

Treatment of hemophilia: a review of current advances and ongoing issues

Antonio Coppola, Mirko Di Capua, Matteo Nicola Dario, et al.

Journal of Blood Medicine 2010, 1:183-195

Published Date: 30 August 2010

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs

Kitty Poon, Allen B King

Drug, Healthcare and Patient Safety 2010, 2:213-223

Published Date: 28 October 2010

Biosensors: the new wave in cancer diagnosis

Brian Bohunicky, Shaker A Mousa

Nanotechnology, Science and Applications 2011, 4:1-10

Published Date: 30 December 2010

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Hedgehog signaling pathway and its targets for treatment in basal cell carcinoma

Cucchi D, Occhione MA, Gulino A, De Smaele E

Journal of Experimental Pharmacology 2012, 4:173-185

Published Date: 17 December 2012